Artal Group’s Intellia Therapeutics NTLA Stock Holding History

Artal Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-276,077	Closed	-$8.73M	–	108
2023 Q3	$8.73M	Hold	276,077	–	–	0.37%	43
2023 Q2	$11.3M	Hold	276,077	–	–	0.35%	45
2023 Q1	$10.3M	Buy	276,077 +1,077	+0.4%	+$42.2K	0.61%	41
2022 Q4	$9.6M	Hold	275,000	–	–	0.54%	44
2022 Q3	$15.4M	Hold	275,000	–	–	0.66%	32
2022 Q2	$14.2M	Hold	275,000	–	–	0.76%	32
2022 Q1	$20M	Hold	275,000	–	–	0.84%	29
2021 Q4	$32.5M	Hold	275,000	–	–	0.88%	29
2021 Q3	$36.9M	Buy	275,000 +25,000	+10%	+$3.79M	0.83%	31
2021 Q2	$40.5M	Hold	250,000	–	–	0.82%	26
2021 Q1	$20.1M	Hold	250,000	–	–	0.35%	66
2020 Q4	$13.6M	Buy	250,000 +60,000	+32%	+$2.18M	0.29%	79
2020 Q3	$3.78M	Sell	190,000 -49,000	-21%	-$1.02M	0.09%	105
2020 Q2	$5.02M	Buy	+239,000	New	+$4.06M	0.14%	106
2020 Q1	–	Sell	-199,700	Closed	-$2.93M	–	112
2019 Q4	$2.93M	Buy	+199,700	New	+$2.78M	0.11%	87
2018 Q4	–	Sell	-90,000	Closed	-$2.58M	–	111
2018 Q3	$2.58M	Hold	90,000	–	–	0.07%	94
2018 Q2	$2.46M	Hold	90,000	–	–	0.05%	90
2018 Q1	$1.9M	Sell	90,000 -160,000	-64%	-$3.93M	0.02%	94
2017 Q4	$4.8M	Buy	250,000 +75,000	+43%	+$1.73M	0.07%	71
2017 Q3	$4.35M	Sell	175,000 -75,000	-30%	-$1.41M	0.07%	69
2017 Q2	$4M	Hold	250,000	–	–	0.07%	74
2017 Q1	$3.52M	Hold	250,000	–	–	0.08%	72
2016 Q4	$3.28M	Buy	250,000 +45,000	+22%	+$676K	0.07%	66
2016 Q3	$3.49M	Sell	205,000 -20,000	-9%	-$387K	0.07%	71
2016 Q2	$4.8M	Buy	+225,000	New	+$5.99M	0.1%	42

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artal Group's NTLA Position: Q4 2023 in Review

Artal Group sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 276,077 shares — an estimated $8.73M sold.

Artal Group first reported a position in NTLA in Q2 2016 and held it in 25 quarters. The position peaked at $40.5M in Q2 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

Artal Group reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
Artal Group sold 276,077 Intellia Therapeutics shares in Q4 2023, an estimated $8.73M.
Artal Group first reported a position in Intellia Therapeutics in Q2 2016 and held it in 25 quarters.
Artal Group's Intellia Therapeutics position peaked at $40.5M in Q2 2021.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.